This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.


  Mobile version   RSS   Subscribe   Unsubscribe   Archive   Media Kit Feb. 14, 2013

   Home   Mission/Vision    Membership    Corporate Membership    CME/CEU    JMCM    Contact Us

Please click here to view Eisai's 2012 Oncology Digest. The PDF contains two articles and the final oncology digest.

Please click here to view the webcast on Eisai's 2012 Oncology Digest from the Fall Managed Care Forum.

Register today
Spring Managed Care Forum
May 2-3, 2013
Gaylord Palms
Orlando, Fla.

Click Here to view the Journal of Managed Care Medicine

Click Here to view our Complimentary Online CME/CEU Webcasts


Announcing the NAMCP Medical Directors Breast Cancer Resource Center. Click here to visit the website.

 




 Genomics

Genetic clues may lead to better grasp of birth defects
Health Canal    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A team of researchers at the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of Southern California has for the first time determined the role of two important molecular signaling pathways that help control the number and position of repeated units of cells that pattern the head and face. More



Genomic data in patients' hands
Genetic Engineering & Biotechnology News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Strides in biotechnology and genomics have enabled individuals to gain access to increasingly more accurate and detailed information about their genomes at decreasing costs. While learning about individual genetic risks and susceptibilities has become more affordable, interpreting the data and establishing the optimal management strategies are opening challenges for both consumers and professionals, and many of these promise to become more pronounced as we approach the $100 genome landmark. More

Newly identified genes may hold the cure to nearsightedness
Medical Daily    Share    Share on FacebookTwitterShare on LinkedinE-mail article
New genes have been shown responsible for myopia, as reported in a report in Nature Genetics. Scientists believe that knowing which genes cause near sightedness may help in developing future treatments. More

 Biotech/Diagnostics/Personalized Medicine


High-content drug screening key for treatment of rare diseases
Laboratory Equipment    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Personalized medicine — tailoring diagnostics and treatment according to individual genetics — is a rapidly growing field. Using advanced screening technologies, the dream of offering customized care to each patient is slowly becoming a reality, offering hope to sufferers of rare diseases, who are often left without medical support. But because each disease impacts only a handful of people worldwide, there is no commercial incentive for pharmaceutical companies to fund drug research and development. More

Discover the Concentra Difference.

Concentra offers medical practice expertise, operational and peer support, and long-term stability to enable your professional and financial success. Our providers work consistent schedules that encourage healthy work-life balance, and experience the satisfaction of working in an environment designed to reduce administrative burden while allowing more time for patient care.


Long-term effects of molecularly targeted therapies in child cancer patients
The Medical News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A University of Colorado Cancer Center review published in the journal Lancet Oncology describes possible long-term side-effects of new, targeted therapies in pediatric cancer patients: what we don't know may hurt us. Already we know that molecularly targeted therapies may stunt the growth of pediatric patients, delay puberty or speed the onset of diabetes. And researchers are just now starting to ask about additional, sometimes unforeseen side-effects, potentially including more subtle issues such as neurocognitive, balance and motor defects. More

 Regenerative Medicine


Brain cells created from human skin cells offer potential MS treatment
Gizmag    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Myelin is a fatty tissue that covers the fibers between nerve cells — it's not unlike the insulation on electrical wiring. When that tissue is compromised, the cells have difficulty communicating, and neurological diseases such as multiple sclerosis can be the result. If the myelin of MS sufferers could be regrown, then it's possible that the disease could be cured. Recently, a team of scientists successfully regenerated myelin in mice, using human skin cells that were reprogrammed into brain cells. More

Research improving breast cancer treatment by targeting tumor initiating cells
Medical Xpress    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A Kansas State University professor's research on breast cancer stem cells may help improve survival rates by preventing cancer recurrence and metastasis — the major causes of death among breast cancer patients. More

 Emerging Medical Technologies


FDA warns of major risk with St. Jude heart device
The Associated Press via Bloomberg Businessweek    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The Food and Drug Administration said that a tool recalled by St. Jude Medical used to insert heart implants could potentially cause serious injury or death if used in patients. The company's Amplatzer TorqVue delivery system is used to mend a type of heart defect that causes holes in the upper chambers of the heart. St. Jude recalled all batches and models of the device recently after a small number of incidents where the delivery system's wire fractured during surgery. More

Federal officials release new EHR format for pediatric care
iHealthBeat    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The Agency for Healthcare Research and Quality and CMS recently released a new electronic health record format for pediatric care. The new format aims to help EHR vendors develop modules that are tailored to children's health needs. Officials said the new format was warranted because current EHR systems are not appropriately set up to capture or process children's health data, resulting in lower EHR adoption rates among pediatric physicians. More

 Managed Healthcare News


$2 billion Medicaid program helps mostly illegal immigrants
Kaiser Health News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
During the debate over the 2010 federal healthcare overhaul, Democrats promised that illegal immigrants wouldn't be among the 27 million people who'd gain coverage. President Barack Obama repeated that pledge last month when he outlined his immigration plan. But while federal law generally bars illegal immigrants from being covered by Medicaid, a little-known part of the state-federal health insurance program for the poor has long paid about $2 billion a year for emergency treatment for a group of patients who, according to hospitals, mostly comprise illegal immigrants. More

Many hospitals unprepared for cost questions
The Associated Press via USA Today    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Want to know how much a hip replacement will cost? Many hospitals won't be able to tell you, at least not right away — if at all. And if you shop around and find centers that can quote a price, the amounts could vary astronomically, a study found. More

 FDA: New Treatments and Technology


Report: FDA not getting key info on risky drugs
The Associated Press via St. Louis Post-Dispatch    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The Food and Drug Administration is not receiving key information from drugmakers about whether some of the riskiest prescription drugs on the market are being used safely by doctors and patients, according a new report by government inspectors. More

New FDA 'breakthrough' status speeds OK
San Francisco Chronicle    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Drugmakers may win approval from U.S. regulators for "breakthrough" therapies after a single round of studies, rather than three, in an effort to speed them to patients, a Food and Drug Administration official said. The agency assigned three promising experimental medicines the new status to try to reduce the time needed to get them to market against life-threatening diseases, the director of FDA's Center for Drug Evaluation and Research said. More

FAST FACTS
"Nearsightedness is very common and affects nearly 30 percent of the U.S. population, according to the American Optometric Association."


 

Genomics Biotech and Emerging Medical Technologies Institute eBrief
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Christine Kraly, Content Editor, 469.420.2685   
Contribute news

This edition of the Genomics Biotech and Emerging Medical Technologies Institute eBrief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!
Recent issues
Feb. 7, 2013
Jan. 31, 2013
Jan. 24, 2013
Jan. 17, 2013



7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063